California-based supplier of gut microbiome and DNA based precision care program for weight loss and associated conditions such as IBS, GERD, hypertension and high cholesterol, Digbi Health, secures a $5.4m Series A funding.
Digbi Health offers a personalised digital care platform in reference to gender and ethnicity as they are the integrated in individuals’ genetic and gut microbiome. It is also the first company to offer a clinically supported genetics and gut-microbiome based program to manage and treat obesity and associated illnesses.
The funding was led by Accel with aid from Wisdom LLP and the company’s Seed round backers Ocean Azul Partners and Seraph Venture. The outcome lies in strengthening teams in the U.S and India for genetic-centered research and associated clinical risk markers. This is in bid to curate precision care for chronic inflammatory illnesses and reverse its associated obesity risk.
Additionally, the company not only hopes to expand its product offering, but reach more payers, employers and Third-party administrator (TPA) partnerships.
Ranjan Sinha, CEO and founder of Digbi Health, explained the mission of the company stating:
We are an innovative telehealth company that supports overburdened physicians by redefining care for 100 million Americans who struggle under one-size-fits-all digital health programs, weight loss diets and stigma of “poor self-control” while fighting obesity and associated inflammatory comorbidities,
As of it’s launch in 2018, it is reported that funding has reached $8.5 million for Digbi Health.
See also: Clinical Research IO (CRIO) secures a $3.5m Series A funding round to give this paper-based industry a digital makeover